newsfilter
← Latest News
GlobeNewswire·

MediWound to Report Fourth Quarter and Full Year 2025 Financial Results

  • MediWound Ltd. (NASDAQ: MDWD) will report financial results for the fourth quarter & full year 2025 on March 5, 2026.
  • Management will host a conference call & live webcast at 8:30 a.m. Eastern Time to discuss results & business highlights.
  • Dial-in numbers include 1-844-676-8833 (toll-free), 1-80-921-2373 (Israel), & 1-412-634-6869 (international).
  • An archived webcast will be available on the Investors section of the MediWound website.
  • The company's FDA-approved product NexoBrid is used for enzymatic eschar removal in thermal burns & marketed in the US, EU, Japan, & other regions.
  • EscharEx is a late-stage investigational therapy for chronic wound debridement with potential to become a new standard of care.
  • MediWound is a global biotechnology company pioneering enzymatic, non-surgical tissue repair therapies.